Search
引用資料與參考文獻 (1)
Invitrogen™
LentiArray™ CRISPR Negative Control Lentivirus, human, non-targeting, with GFP
Negative control gRNAs are essential in screening applications for setting thresholds for hit determination. The Invitrogen™ LentiArray™ CRISPR Negative Control深入閱讀
Have Questions?
變更視圖
| 產品號碼 | Quantity |
|---|---|
| A32063 | 100 μL |
| A32831 | 1 mL |
產品號碼 A32063
價格 (TWD)
18,130.00
Online offer
Ends: 31-Dec-2025
25,900.00您節省 7,770.00 (30%)
Each
Quantity:
100 μL
價格 (TWD)
18,130.00
Online offer
Ends: 31-Dec-2025
25,900.00您節省 7,770.00 (30%)
Each
Negative control gRNAs are essential in screening applications for setting thresholds for hit determination. The Invitrogen™ LentiArray™ CRISPR Negative Control Lentivirus, Human Scrambled, contains a gRNA sequence with no sequence homology to any region of the human genome. This construct also expresses emGFP to provide a visual readout of successful transduction that can be used in determining Multiplicity of Infection (MOI).
For Research Use Only. Not for use in diagnostic procedures.
規格
Delivery TypeLentiviral
For Use With (Application)Genome Editing
Product LineLentiArray
Product TypegRNA
PromoterU6
Quantity100 μL
Shipping ConditionDry Ice
Control TypeNegative Control
FormatTube
RNAi TypegRNA
SpeciesHuman
Unit SizeEach
內容物與存放
1 x 100 μL. Store (at -68°C to -85°C.)
引用資料與參考文獻 (1)
引用資料與參考文獻
Abstract
A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
Journal:Pediatr Blood Cancer
PubMed ID:28398638
Malignant rhabdoid tumors (MRTs) are deadly embryonal tumors of the infancy. With poor survival and modest response to available therapies, more effective and less toxic treatments are needed. We hypothesized that a systematic screening of the kinome will reveal kinases that drive rhabdoid tumors and can be targeted by specific